Industry-Leading Early Phase Clinical Development Capabilities
Moving quickly and safely through early-phase clinical trials is essential to achieving success in the drug development process. At QPS, a global, full-service CRO, we specialize in guiding sponsors through these critical first steps with unmatched expertise, cutting-edge facilities, and a global reach.
QPS is well known for its success in first-in-human clinical trials. All Phase I sites are staffed by expert clinical pharmacology teams that routinely conduct hundreds of Phase I/IIa studies annually. We also have scientific expertise in the design and execution of all types of early phase clinical studies including Proof of Concept, First in Human, SAD/MAD dose response, Drug-Drug Interaction, BA/BE and PK/PD studies, as well as comprehensive back end CRO services, including the interpretation of study data.
We specialize in conducting proof-of-concept (POC) studies. Our proof-of-concept studies help ensure a study’s safety and value and prevent resources from being wasted on targets and molecules that aren’t likely to succeed. When well-designed and properly conducted, proof-of-concept studies establish the basis for larger-scale dose-response, efficacy, and safety studies that will assess efficacy, tolerability, side effects, and associated risks.
Our early phase clinical research facilities feature more than 500 beds strategically globally located, ensuring access to diverse patient populations and streamlined study execution.
Our expert clinical pharmacology teams have a proven track record, conducting hundreds of Phase I and IIa studies annually. We excel in designing, managing, and interpreting early-phase studies with precision, ensuring reliable results and actionable insights.
Proven Expertise in Early Phase Clinical Trials
Comprehensive Early-Phase Trial Capabilities in Global Clinical Research Units
Global Reach and Expertise
- Springfield, Missouri, USA: 240 beds
- South Miami, Florida, USA: 106 beds
- Hyderabad, India: 138 beds
- Taipei, Taiwan: 40 beds (in partnership with local hospitals)
In addition to >500 Phase I patient beds around the world, QPS has established partnerships with more than 700 early phase clinical trial units and late phase clinical trial sites in the Americas, Europe, Asia and Australia. Our comprehensive global, full-service CRO research services offerings can be found here: https://www.qps.com/service/clinical-research-services/.
Australia’s Unique Advantages
QPS has an established CRO office and a network of partners in Australia. A few of these sites exclusively run Phase I-IIa oncology trials and have deep experience with running these challenging studies. If you choose to run your study in Australia, there are some additional potential benefits, such as shorter timelines and a research tax credit for smaller biotech companies. QPS can connect you with a consulting company to learn more, while we discuss your potential project.
Additional information on how QPS can support your trial in Australia, can be found here https://www.qps.com/service/oncology-clinical-research/.
In addition to one of the world’s largest Phase I site offerings, we provide fully integrated services to seamlessly move your project from first-in-human clinical trials through early clinical development. QPS’s large, global bioanalytical labs support this early phase clinical study work by defining pharmacodynamic endpoints and developing laboratory biomarker assays for the evaluation of your early-stage compounds, targeted for a wide variety of therapeutic indications.
Our expert staff uses disciplined processes to supply accurate, superior-quality data so you can make confident decisions – earlier and faster.
QPS: Your Partner for Phase I/IIa Excellence
QPS is a leader in first-in-human (FIH) clinical trials, with extensive experience across a wide range of study types, including:
Proof-of-concept (POC) studies are a cornerstone of early-phase clinical development. These studies are designed to determine a drug’s safety and effectiveness, laying the groundwork for subsequent large-scale trials. At QPS, we conduct POC studies in a variety of study subject populations, providing critical data to guide your development strategy
Our well-designed POC studies:
- Minimize resource waste on targets or molecules unlikely to succeed.
- Provide clear, actionable insights into efficacy, tolerability, and safety.
- Establish a robust foundation for dose-response, efficacy, and safety assessments in later phases.
SAD and MAD clinical studies are types of dose-escalation studies conducted primarily in early-phase clinical trials, particularly in the context of Phase I studies.
- These studies are used to evaluate the safety, tolerability, pharmacokinetics (PK), and sometimes pharmacodynamics (PD) of a new drug or investigational product in healthy volunteers or, in certain cases, patient populations.
- The primary aim of both SAD and MAD studies is to determine the maximum tolerated dose (MTD) and inform dose selection for subsequent trials.
SAD and MAD studies are essential for assessing the safety, tolerability, and pharmacokinetics of a new drug or biologic.
- The primary goal of the SAD study is to determine the safety profile after a single dose and establish the maximum tolerated dose (MTD).
- The MAD study, on the other hand, focuses on assessing the safety and pharmacokinetics of repeated doses, providing data to determine the appropriate dosing regimen for future clinical trials.
|
Feature
|
Single Ascending Dose (SAD)
|
Multiple Ascending Dose (MAD)
|
|---|---|---|
Feature
Number of Doses
|
Single Ascending Dose (SAD)
Participants receive a single dose of the investigational drug.
|
Multiple Ascending Dose (MAD)
Participants receive multiple doses over several days/weeks.
|
Feature
Primary Focus
|
Single Ascending Dose (SAD)
Safety and PK with a single dose.
|
Multiple Ascending Dose (MAD)
Safety, tolerability, and PK/PD with repeated dosing.
|
Feature
Purpose
|
Single Ascending Dose (SAD)
Assess how the drug behaves after a single dose.
|
Multiple Ascending Dose (MAD)
Assess how the drug behaves after repeated dosing.
|
Feature
Study Duration
|
Single Ascending Dose (SAD)
Typically shorter duration (several hours to a few days).
|
Multiple Ascending Dose (MAD)
Longer duration (several days to weeks).
|
Feature
Key Endpoints
|
Single Ascending Dose (SAD)
Maximum tolerated dose (MTD), pharmacokinetics after a single dose.
|
Multiple Ascending Dose (MAD)
Cumulative effect, steady-state pharmacokinetics, long-term safety and tolerability.
|
Feature
Focus on Cumulative Effects
|
Single Ascending Dose (SAD)
No (only single-dose effects are evaluated).
|
Multiple Ascending Dose (MAD)
Yes (cumulative or long-term effects are monitored).
|
DDI studies are clinical studies conducted to evaluate the potential interactions between two or more drugs when taken together. These interactions can affect the pharmacokinetics (PK) or pharmacodynamics (PD) of one or more of the drugs involved, potentially leading to adverse effects, reduced efficacy, or unexpected drug behavior. DDI studies are crucial for understanding how drugs influence each other’s absorption, distribution, metabolism, excretion, and overall effectiveness.
The primary goal of a DDI study is to assess whether one drug affects the pharmacokinetics (PK) or pharmacodynamics (PD) of another drug when co-administered.
Key areas that are assessed include:
- Pharmacokinetics (PK) Interactions:
- Absorption: How one drug may affect the absorption rate or extent of another drug.
- Metabolism:The impact of one drug on the enzyme systems (especially cytochrome P450 enzymes) that metabolize the other drug.
- Excretion: Whether one drug alters the elimination or clearance of another drug from the body.
- Protein Binding: Some drugs may compete for binding sites on plasma proteins, leading to changes in the free (active) concentration of another drug.
- Pharmacodynamics (PD) Interactions:
- How drugs may alter each other’s pharmacological effects (e.g., additive or antagonistic effects).
- Safety and Efficacy:
- Identifying potential toxicities, adverse events (AEs), or altered therapeutic effects when drugs are used in combination.
DDI studies are essential for understanding how drugs interact when co-administered, influencing their safety, efficacy, and overall pharmacokinetic profiles. By evaluating both pharmacokinetic and pharmacodynamic interactions, these studies help inform drug dosing strategies, minimize the risks of adverse effects, and improve therapeutic outcomes. DDI studies are an integral part of early-phase clinical trials, guiding regulatory approval processes and safe clinical practice.
Food Effect studies are clinical trials designed to evaluate how food intake influences the pharmacokinetics (PK) of a drug. These studies are important because food can affect the absorption, distribution, metabolism, and excretion (ADME) of drugs, which may influence their efficacy and safety. Understanding food effects is crucial for determining the best way for patients to take a drug (e.g., with or without food) to ensure optimal therapeutic outcomes.
Several classes of drugs can have their pharmacokinetics significantly affected by food:
- Antiretrovirals (e.g., protease inhibitors like ritonavir): Often recommended to be taken with food to improve absorption.
- Antibiotics (e.g., doxycycline): Some antibiotics, like tetracyclines, are less effective when taken with dairy products due to binding to calcium.
- Statins (e.g., atorvastatin): Certain statins may be absorbed better when taken with food, but the effect can vary between different statins.
- Tyrosine Kinase Inhibitors (e.g., imatinib): These drugs can have altered absorption with food, affecting their efficacy.
Food Effect studies are crucial in drug development to understand how food impacts the absorption, distribution, and overall pharmacokinetics of oral medications. The results of these studies are used to inform labeling recommendations, ensuring that patients take medications in a way that optimizes their efficacy and minimizes potential side effects. These studies also help clinicians guide patients in the correct administration of drugs, considering potential interactions with food.
Purpose of PK/PD Studies:
- Pharmacokinetics (PK): Describes the absorption, distribution, metabolism, and elimination (ADME) of a drug in the body.
- Absorption: How the drug enters the bloodstream (e.g., oral, intravenous).
- Distribution: How the drug spreads throughout the body’s tissues and organs.
- Metabolism: How the drug is chemically altered by enzymes, often in the liver.
- Elimination: How the drug and its metabolites are excreted, typically through the kidneys or bile.
- Pharmacodynamics (PD): Describes the biochemical and physiological effects of the drug on the body, including the relationship between drug concentration and effect.
- Receptor Binding: How the drug interacts with its target receptor(s).
- Mechanism of Action: The biochemical pathway that leads to the drug’s effect.
- Effect on Organs/Tissues: How the drug causes changes at the organ or tissue level.
- Elimination: How the drug and its metabolites are excreted, typically through the kidneys or bile.
- Dose-Response Relationship: The relationship between the dose of the drug and the magnitude of the effect.
By combining PK and PD, researchers can:
- Determine the optimal dose that achieves the desired therapeutic effect with minimal toxicity.
- Understand the time course of drug effects (e.g., when to dose and how often).
- Identify factors that influence individual variability in drug response (e.g., age, genetics, disease status).
Bioavailability (BA) Studies
Bioavailability (BA) refers to the rate and extent to which the active ingredient of a drug reaches the systemic circulation and is available for therapeutic action at the site of action. The primary goal of a BA study is to assess how much of the drug reaches the bloodstream after administration and how quickly it does so.
Key Components of BA Studies:
- Absorption: The process by which the drug is taken up from the gastrointestinal tract into the bloodstream.
- Rate and Extent of Absorption: The key parameters for assessing bioavailability are:
- Cmax (Maximum Concentration): The peak plasma concentration of the drug.
- AUC (Area Under the Curve): The total drug exposure over time, which reflects the total amount of the drug that reaches systemic circulation.
- Half-Life (T1/2): The time it takes for the concentration of the drug in the plasma to reduce by half.
Pusrpose of BA Studies:
- To determine how much of the drug is absorbed and how fast, which impacts its therapeutic effectiveness.
- To help in formulating the most effective drug dosage forms (e.g., tablets, injections, etc.).
- To assess the potential influence of food, disease, age, or other factors on the drug's absorption.
Methods Used in BA Studies:
- BA studies typically involve the measurement of plasma drug concentrations after administering the drug. Blood samples are taken at various time points to plot concentration vs. time profiles.
- The study may be conducted under fasted or fed conditions, as food can significantly impact the drug’s absorption.
Bioequivalence (BE) Studies
BE studies compare the bioavailability of two different drug products, typically a generic version and the brand-name drug (reference product), to ensure they are therapeutically equivalent. Two drug products are considered bioequivalent if they deliver the same amount of the active ingredient to the bloodstream in the same amount of time under similar conditions.
Key Objectives of BE Studies:
- To demonstrate that the generic drug performs similarly to the brand-name product in terms of rate and extent of absorption, ensuring they have the same therapeutic effect and safety profile.
- To ensure that generic drugs can be substituted for the brand-name product without compromising therapeutic efficacy or safety.
Key Parameters for BE Studies:
The most commonly measured pharmacokinetic parameters to assess bioequivalence are:
- Cmax: The peak plasma concentration of the drug after administration.
- Tmax: The time at which the Cmax occurs.
- AUC (Area Under the Curve): The total exposure to the drug in the bloodstream over time, which reflects the total amount of drug absorbed.
The two drug products are considered bioequivalent if the 90% confidence intervals of the geometric mean ratio for Cmax and AUC fall within an acceptable range, typically 80% to 125%. This range ensures that any differences in absorption are not clinically significant.
Integrated Services for Seamless Early-Phase Development
- Study Design and Protocol Writing
- Regulatory Support
- Data Management, Statistics & Pharmacokinetics, and Medical Writing
- Bioanalysis/Biomarker Assays/Genotyping
- On-site PBMC Processing and FACs Analysis
- Pharmacy and Compounding Capabilities - page coming soon!
- First-in-Man Programs (SAD + MAD + FE + gender)
From First-in-Human to Early Clinical Development
- Global Bioanalytical Laboratories: Advanced bioanalytical capabilities to define pharmacodynamic endpoints and develop biomarker assays.
- Therapeutic Expertise: A wide range of indications, from oncology and CNS to cardiometabolic and endocrine diseases.
- Comprehensive Data Support: Accurate and high-quality data to enable confident decision-making, faster.
Why Choose QPS for Early-Phase Clinical Trials?
- Global Presence: Access to diverse populations and regulatory environments.
- Extensive Experience: Hundreds of studies conducted annually across various therapeutic areas.
- End-to-End Integration: Seamless transition from early phase to late-stage development.
- Specialized Expertise: Dedicated facilities and teams for complex studies, including oncology and rare diseases.
- Commitment to Quality: Data you can trust, delivered on time and on budget.
Partner with QPS to accelerate your drug development journey and bring your innovations to life. Contact us today to learn how we can support your early-phase clinical trial needs.
Links to Relevant Documents
- Clinical Trials in Special Populations
- Early Phase Clinical Overview
- Expedited Study Delivery – Logistics
- Expedited Study Delivery – Pharmacy
- Studying Sedatives in Phase I Studies
- Pharmacokinetic Studies in Patients
- 2021 QPS NL Clinical Study Infographic
- Selecting the Location of a Phase I Clinical Trial in the EU
- QPS Negative Pressure Room
- CNS Drug Development
- Influenza Vaccine Case Study
- Clinical Trial Complexity in a Pandemic Case Study
- Corporate Overview Clinical Sites
